DK0474098T3 - Middel til kontrolleret lægemiddelfrigivelse - Google Patents

Middel til kontrolleret lægemiddelfrigivelse

Info

Publication number
DK0474098T3
DK0474098T3 DK91114374.1T DK91114374T DK0474098T3 DK 0474098 T3 DK0474098 T3 DK 0474098T3 DK 91114374 T DK91114374 T DK 91114374T DK 0474098 T3 DK0474098 T3 DK 0474098T3
Authority
DK
Denmark
Prior art keywords
drug release
controlled drug
release agent
macromolecular compound
composition
Prior art date
Application number
DK91114374.1T
Other languages
Danish (da)
English (en)
Inventor
Yasushi Morita
Akira Ohtori
Masako Andoh
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of DK0474098T3 publication Critical patent/DK0474098T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK91114374.1T 1990-08-30 1991-08-27 Middel til kontrolleret lægemiddelfrigivelse DK0474098T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22988790 1990-08-30

Publications (1)

Publication Number Publication Date
DK0474098T3 true DK0474098T3 (da) 1994-05-02

Family

ID=16899272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91114374.1T DK0474098T3 (da) 1990-08-30 1991-08-27 Middel til kontrolleret lægemiddelfrigivelse

Country Status (10)

Country Link
US (1) US5183662A (de)
EP (1) EP0474098B1 (de)
JP (1) JP3934684B2 (de)
KR (1) KR970009579B1 (de)
AT (1) ATE102022T1 (de)
CA (1) CA2050067C (de)
DE (1) DE69101291T2 (de)
DK (1) DK0474098T3 (de)
ES (1) ES2062634T3 (de)
RU (1) RU2053769C1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301823A (es) * 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AU2003221497A1 (en) 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
AU2003208245A1 (en) * 2002-03-15 2003-09-29 Kuyus, Stiftung Composition and utilization thereof for forming a protective film on nasal mucous membranes
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006102378A2 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
KR100871988B1 (ko) 2007-06-25 2008-12-05 한국과학기술원 수용성 용매 없이 수용성 거대분자 약물이 봉입된 생분해성미립구 담체의 제조방법 및 생분해성 미립구 담체
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2723588A1 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated uses
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1391554A (en) * 1972-08-03 1975-04-23 Beecham Group Ltd Pharmaceutical compositions and process for their preparation
US4048256A (en) * 1976-06-01 1977-09-13 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
DE2856901D2 (de) * 1977-06-07 1980-11-13 Garching Instrumente Form of implant medicament and preparation process
GB2091554B (en) * 1981-01-13 1984-09-12 Mitsui Toatsu Chemicals Rod like moulded drug
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules

Also Published As

Publication number Publication date
KR920003973A (ko) 1992-03-27
ATE102022T1 (de) 1994-03-15
JPH054924A (ja) 1993-01-14
CA2050067C (en) 2000-05-30
KR970009579B1 (ko) 1997-06-14
DE69101291D1 (de) 1994-04-07
DE69101291T2 (de) 1994-07-07
JP3934684B2 (ja) 2007-06-20
CA2050067A1 (en) 1992-03-01
EP0474098B1 (de) 1994-03-02
EP0474098A1 (de) 1992-03-11
US5183662A (en) 1993-02-02
RU2053769C1 (ru) 1996-02-10
ES2062634T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
DK0474098T3 (da) Middel til kontrolleret lægemiddelfrigivelse
IT1255449B (it) Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
ES2120562T3 (es) Composicion farmaceutica de liberacion sostenida.
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
DK0643963T3 (da) Biologisk nedbrydelig indretning til indgivelse af virksomme stoffer
DE69014684D1 (de) Biologisch abbaubare Polyphosphoester.
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
BG27874A3 (en) Insecticide means and method for insecticide fighting
ES2060415T3 (es) 1,3-bis(3-(mono- o poli-hidroxi)acilamino-5-(mono- o polihidroxialquil)aminocarbonil-2,4,6-triyodo-benzoilamino)hidroxi- o hidroxialquil-propanos, procedimiento para su preparacion y medios de contraste para rayos x que los contienen.
ATE433753T1 (de) Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe
ES491307A0 (es) Un procedimiento para la preparacion de una composicion de liberacion controlada de un compuesto biologicamente activo para su administracion a un animal
ES2059625T3 (es) Un procedimiento para preparar un derivado de hidroxialquilcisteina.
ATE306475T1 (de) Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung
ATE131725T1 (de) Formulierungen zur behandlung der vaginalen trockenheit
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.
MX9100348A (es) Copolimero de bloque,hidrogenado y ramificado,y procedimiento para su preparacion
IT8721687A0 (it) Derivati dell'ossima della 1,2,5,6-tetraidropiridin-3-carbossa ldeide, loro procedimento di preparazione e loro impiego come sostanze medicinali.
DK183582A (da) Fremgangsmaade til fremstilling af oxazolderivater
ES2118818T3 (es) Tiazolin-2-onas aminoalquil-substituidas, su obtencion y empleo.
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
DK0730861T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til fremstilling af farmaceutiske præparater, der er nyttige til behandli
KR930007349A (ko) 종자 처리용 식물 질병-억제 조성물
JPS5241244A (en) Sustained release aromatic composition and method of making the same
BR9106740A (pt) Formulacao diluidora proporcionando propriedades de sustentacao a produtos agricolas